Psychedelic and ketamine research trials in Finland
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
3 registered studies are counted in Finland. By compound: 3 ketamine. By registry status: 1 not yet recruiting, 1 completed and 1 status not reported. By phase: 3 phase 1. Reported start years run from 2018 (earliest) to 2026 (latest). Studies are linked to 2 institutions.
Country is taken from the research site linked to each registry record. A study counts once, and a study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
Recruiting now
1 of the 3 counted studies is listed in the registry as recruiting (0) or not yet recruiting (1), newest start first. Status is reported by study teams and can be out of date. PsychoactiveMap does not recruit, screen or refer anyone; eligibility and contact details are on each registry record.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study | NCT07462559 | Not yet recruiting | Phase 1 | 2026-03-04 | Helsinki University Central Hospital, Helsinki |
At a glance
- 3 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Ketamine | 3 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Not yet recruiting | 1 | 33% |
| Completed | 1 | 33% |
| Status not reported | 1 | 33% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 1 | 3 | 100% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 2 |
| 2015 to 2019 | 1 |
All counted studies
All 3 counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study | NCT07462559 | Not yet recruiting | Phase 1 | 2026-03-04 | Helsinki University Central Hospital, Helsinki |
| KF2024#1-trial: Esketamine Interaction Study | NCT06726382 | Completed | Phase 1 | 2024-12-09 | Helsinki University Central Hospital, Helsinki |
| Touchscreen-based Cognitive Tests in Healthy Volunteers | NCT03469089 | Status not reported | Phase 1 | 2018-03-12 | University of Eastern Finland, Kuopio |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Other country hubs
United States | Canada | Switzerland | United Kingdom | France | Israel | Brazil | China | Netherlands | Australia | Austria | Germany | Spain | Sweden | Argentina | Belgium | Egypt | Mexico | Poland | Taiwan | Ireland | Czech Republic | Denmark